News | February 03, 2010

Study Shows Safety, Effectiveness of Laser Assisted Lead Removal

February 3, 2010 – Results of a four-year study evaluating the safety and efficacy of laser assisted lead removal using the Spectranetics laser sheath (SLS II), found a 97.7 percent clinical success rate.

Data from the LExICon (Lead Extraction in Contemporary Settings) study, is published in the Feb. 9 issue of the Journal of American College of Cardiology. In addition to the high rate of success, the observational, multicenter, retrospective study, found a low 1.4 percent major adverse event rate, 0.28 percent procedural mortality rate, and that procedural failure is highly associated with lead implant duration greater-than or equal to 10 years.

The study sought to determine clinical and procedural success and complication types, and identify relationships between complication factors including duration of implant, lead type, lead position, center experience, age and gender. LExICon evaluated the removal of 2,405 leads in 1,449 patients at 13 centers experienced in lead extraction from the United States and Canada between January 2004 and December 2007.

"Indications for lead removal fall into three basic categories, infection, lead malfunction and access for new leads," said Bruce Wilkoff, M.D., principle investigator of the study, and director of cardiac pacing and tachyarrhythmia devices at Cleveland Clinic. "Lead abandonment is still reasonable under some circumstances, but it is no longer the clear standard of care. The LExICon study quantifies the risks of laser assisted lead removal and illustrates the clear benefits for many patients. It is the responsibility of physicians to be trained on all safe and effective lead management techniques to ensure patients receive the highest possible quality of care."

Infection is a common reason for considering lead removal. In the LExICon study, infection was the most frequent indication for removal, accounting for 57 percent of the removal procedures. Even though patients with either a pocket infection or device-related endocarditis (DRE) including sepsis and bacteremia had a higher overall mortality than patients without infections, there was no statistical difference in extraction success or extraction procedure mortality for patients without infection, pocket infections or patients with DRE. Consequently, the data supported that there is often more risk from the infection, particularly in the setting of renal insufficiency or diabetes than there is from the lead removal in experienced extraction centers.

The study also examined the challenges of removing leads after increased time and found greater procedural failure when leads have been implanted for greater than or equal to 10 years. This illustrates the importance of a proactive lead management strategy that aligns with the 2009 Heart Rhythm Society Expert Consensus statement about lead removal.

The Spectranetics laser sheath uses low temperature ultraviolet light to safely, effectively and efficiently ablate scar tissue holding problematic leads in place. A circle of fibers emit pulses of laser energy traveling over the cardiac lead towards the tip to break down scar tissue binding the lead to the vein or heart, permitting the lead to be safely removed. Spectranetics' LLD EZ Lead Locking Device technology can also be used to assist removal by creating traction on the lead while the laser sheath is advanced over it.

For more information:

Related Content

Trial Data Shows Positive Predictive Results for Boston Scientific HeartLogic Heart Failure Diagnostic
News | Heart Failure| October 20, 2017
October 20, 2017 — Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart F
Cardiovascular Risk Significantly Higher in Women With Fatty Liver Disease
News | Womens Healthcare| October 20, 2017
Nonalcoholic fatty liver disease (NAFLD) is associated with significantly higher risk of subsequent cardiovascular...
Smartphone Apps Help Patients and Providers Manage Atrial Fibrillation
News | Patient Engagement| October 19, 2017
October 19, 2017 — Novel smartphone and tablet applications for atrial fibrillation patients and healthcare professio
Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
The Respicardia Remede System is a pacemaker-like device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with Central sleep apnea.
Technology | Heart Failure| October 18, 2017
October 18, 2017 — The U.S.
MRI May Predict Neurological Outcomes for Cardiac Arrest Survivors
News | Sudden Cardiac Arrest| October 18, 2017
Magnetic resonance imaging (MRI)-based measurements of the functional connections in the brain can help predict long-...
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab| October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
Overlay Init